Registry of Patients With Plasma Cell Disorders
- Conditions
- Plasma Cell Disorders
- Registration Number
- NCT06286215
- Lead Sponsor
- Siriraj Hospital
- Brief Summary
The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:
* The incidence of plasma cell disorders both before and after malignancy
* Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
* Progression free survival (PFS)
* overall survival
* factors influencing overall survival, progression-free survival, and time to progression
* Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.
* genetic characteristics of plasma cell disorder
* cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 750
- Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014
- Aged 18 years and above
- insufficient data needed for analysis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method register the plasma cell disorder patients 10 years register the plasma cell disorder patients
- Secondary Outcome Measures
Name Time Method overall survival 10 years overall survival
Progression free survival 10 years Progression free survival
incidence of plasma cell disorders 10 years incidence of plasma cell disorders both before and after malignancy
influencing factors 10 years factors influencing overall survival, progression-free survival, and time to progression
cost-effectiveness 10 years cost-effectiveness of treatment in Thailand
Time to progression 10 years - Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
Symptoms and signs 10 years Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients
genetic characteristics 10 years genetic characteristics of plasma cell disorder